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SUMMARY
Objective: Epileptic encephalopathy (EE) is a heterogeneous condition associated with
deteriorations of cognitive, sensory and/ormotor functions as a consequence of epilep-
tic activity. The phenomenon is the most common and severe in infancy and early
childhood. Genetic-based diagnosis in EE patients is challenging owing to genetic and
phenotypic heterogeneity of numerous monogenic disorders and the fact that thou-
sands of genes are involved in neurodevelopment. Therefore, high-throughput next-
generation sequencing (NGS) was used to investigate the genetic causes of non-syn-
dromic cryptogenic neonatal/infantile EE (NIEE).
Methods: We have selected a cohort of 31 patients with seizure cryptogenic NIEE and
seizure onset before 24 months. All investigations including metabolic work-up, were
negative. Using NGS, we distinguished a panel of 430 epilepsy-associated genes by
NGS was utilized to identify possible pathogenic variants in the patients. Segregation
analysis andmultiple silico analysis prediction tools were used for pathogenicity assess-
ment. The identified variants were classified as “pathogenic,” “likely pathogenic” and
“uncertain significance,” according to the American College of Medical Genetics
(ACMG) guidelines.
Results: Pathogenic or likely pathogenic variants were identified in six genes (ALG13
[1], CDKL5 [2], KCNQ2 [2], PNPO [1], SCN8A [1], SLC9A6 [2]) in 9 NIEE patients (9/31;
29%). Variants of uncertain significance (VUS) were found in DNM1 and TUBA8 in 2
NIEE patients (2/31; 6%). Most phenotypes in our cohort matched with those reported
cases.
Significance: The diagnostic rate (29%) of pathogenic and likely pathogenic variants
was comparable to the recent studies of early-onset epileptic encephalopathy, indicat-
ing that gene panel analysis through NGS is a powerful tool to investigate cryptogenic
NIEE in patients. Six percent of patients had neurometabolic disorders. Some of our
diagnosed cases illustrated that successful molecular investigation may allow a better
treatment strategy and avoid unnecessary and even invasive investigations. Functional
analysis could be performed to further study the pathogenicity of the VUS identified in
DNM1 and TUBA8.
KEYWORDS: Epilepsy, Epileptic encephalopathy, Next-generation sequencing, Neu-
rodevelopment, Seizure.
Epileptic Encephalopathies (EEs) are heterogeneous con-
ditions in which motor, sensory, and/or cognitive function
deterioration results mainly from epileptic activity, which
consists of frequent seizures and/or major interictal
paroxysmal activity.1 EE may occur at any age, but the phe-
nomenon is most common and severe in infancy and early
childhood, which is the most critical period of brain matura-
tion.2 Although well-known EE such as Dravet syndrome,
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Ohtahara syndrome, West syndrome, and migrating focal
epilepsy of infancy are recognized by the International Lea-
gue Against Epilepsy (ILAE), the majority of infants are
non-syndromic and do not strictly fit into the defined elec-
troclinical phenotypes of these syndromes.3
Etiology of EE can be congenital structural brain abnor-
malities, neurometabolic disorders, recognizable dysmor-
phic syndromes, or chromosomal, monogenic or
environmental causes.4 Structural brain abnormalities,
either congenital (such as cortical malformations) or
acquired (such as hypoxic ischemic insults), are the most
common cause of early onset EE while neurometabolic dis-
orders are the potentially treatable rare cause.3 If imaging
and metabolic tests fail to identify etiology, genetic-based
diagnosis is important so that exhaustive and invasive test-
ing can be avoided. On the other hand, it is challenging
because of the genetic and phenotypic heterogeneity associ-
ated with particular gene variants.5 In addition, thousands of
genes are involved in neurodevelopment and the number of
potential pathogenic variants is too high to be screened by
traditional Sanger sequencing. The rapid development and
lower cost of high throughput next-generation sequencing
(NGS), allows such technology to be used for discovery of
causal and predisposing gene variants associated with EE.
In recent studies, we proposed using Sanger sequenc-
ing of our selected panel of seven genes (ARX, CDKL5,
KCNQ2, PCDH19, SCN1A, SCN2A and STXBP1) as an
option for genetic diagnosis in small-scale mutational
studies.6 We have identified 13 variants (46%) within
this panel in 28 non-syndromic neonatal/infantile EE
(NIEE) patients without clinical signs suggestive of a
clear genetic syndrome, such as dysmorphic features or
positive findings after extensive metabolic and neu-
roimaging studies.6–8 Despite this, the underlying etiol-
ogy of the remaining patients with negative findings
remained unexplained. In the present study, we have
applied gene panel analysis of 430 epilepsy-associated
genes in 31 non-syndromic cryptogenic NIEE patients
for genetic-based diagnosis and subsequent potential
treatment strategy.
Methods
Patient samples and clinical diagnosis
The study was conducted in Queen Mary Hospital and
Duchess of Kent Children’s Hospital, two affiliated hospi-
tals of the University of Hong Kong. The selection crite-
ria and clinical assessments of the nonsyndromic NIEE
patients have been described in our previous study.6 We
included patients who satisfied the ILAE definition of
EE, with seizure onset before 24 months of age, and who
have been actively followed up in our centre. Patients
with a definite history of brain insult, malformation of
cortical development, neurocutaneous and syndromal dis-
orders, and confirmed or highly suspected neurometabolic
disorders based on clinical and biochemical markers were
excluded. Patients who fit into distinct electroclinical syn-
dromes proposed by the ILAE when candidate gene
approach is straightforward, in particular Dravet syn-
drome and epilepsy of infancy with migrating focal sei-
zures, were also excluded because the majority of
variants are detected in the SCN1A (>85%) and KCNT1
(~50%) genes, respectively.9
Data variables collected from the medical charts
included demographic information (sex, ethnicity, age at
seizure onset and latest follow-up), family history (febrile
convulsion, epilepsy, intellectual disability and other neu-
rological diseases), epilepsy details (seizure types at onset
and latest follow-up, seizure frequency and evolution, cur-
rent number of antiepileptic medications), neurological
examination findings, and other associated clinical fea-
tures (such as autism spectrum disorder, visual and hear-
ing impairment). Information regarding the developmental
status at the latest follow-up was collected as well. Either
formal neuropsychological testing (using Griffiths Mental
Developmental Scale or Hong Kong-Wechsler Intelli-
gence Scale for Children) or best clinical assessment
(based on developmental milestones recorded in the medi-
cal charts) was used to classify development or intelli-
gence as normal, mildly delayed, moderately delayed or
severely delayed.
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Key Points
• Pathogenic or likely pathogenic variants were identi-
fied in six genes (ALG13, CDKL5, KCNQ2, PNPO,
SCN8A, and SLC9A6) in 9 non-syndromic cryptogenic
NIEE patients
• Variant of uncertain significance (VUS) was found in
DNM1 and TUBA8 in another 2 NIEE patients
• The diagnostic yield of pathogenic or likely patho-
genic variants was 29% (9/31)
• Next-generation sequencing with gene panel analysis
is a powerful tool to investigate NIEE patients with
unexplained etiologies
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Whole exome sequencing and gene panel filtering
Blood sample collection from all participants for genetic
study was approved by the Institutional Review Board of
the Hong Kong West Cluster and the University of Hong
Kong (IRB Ref. No.: UW 11-190). Written informed con-
sent was obtained from the parents of the NIEE patients.
Genomic DNA samples were extracted from peripheral
blood using Flexigene DNA Kit (Qiagen GmbH, Germany).
Quality of genomic DNA was evaluated by agarose gel
analysis and quantity was measured by Qubit dsDNA assay
(Thermo Fisher Scientific, Waltham, MA, U.S.A.).
The genomic DNA sample library was prepared using
KAPA Library Preparation Kit, Illumina platforms (KAPA
Biosystem, Boston, MA, U.S.A.). DNA target regions were
captured by hybridizing the genomic DNA sample library
with the SeqCap EZ Human Exome Library v.3.0 (64-Mb
exome) (Roche NimbleGen, Basel, Switzerland). The cap-
tured and amplified DNA samples were sequenced using
Illumina Hiseq 1500 sequencer (Illumina, San Diego, CA,
U.S.A.) with 101 base-paired end reads.
The raw sequencing reads were first filtered to remove
adaptor sequence and low-quality sequence by retaining
only reads with read length ≥40 bp. The filtered reads were
mapped to the human genome using BWA Version 0.6.2
software with default parameters. The mapped reads were
then split into on and off target reads and duplicated reads in
the on target reads were removed by Picard Version 1.73
tools. Local realignment, base quality recalibration and
variants calling (both SNP and Indels) were performed by
GATK Version 3.2-2 using default parameters. Raw vari-
ants were filtered as recommended by the GATK authors.
The final lists of variants were annotated by Annovar for
examination of allele frequency, prediction of potential
functional impact of the coding variants (missense, non-
sense, or frameshift), and reporting the score of pathogenic-
ity assessment. The National Heart, Lung, and Blood
Institute Grand Opportunity Exome Sequencing Project
(NHLBI GO ESP) with 6,500 exomes and 1,000 genome
project datasets was used to assess the allele frequency in
the control population; we considered variants with a fre-
quency of <1%.
The variants called from whole exome sequencing
(WES) were filtered in a panel of 430 epilepsy-associated
genes. The panel (Table 1) included (1) genes associated
with early infantile EE (EIEE) and EE in the Online Men-
delian Inheritance in Man (OMIM) database (http://www.
ncbi.nlm.nih.gov/omim), (2) candidate genes identified in
exome studies, (3) candidate genes from EE or epilepsy-
associated copy number variation (CNV) studies5,10 and (4)
genes related to epilepsy or other neurodevelopmental dis-
eases with most of them selected from a panel suggested by
Lemke et al..11 After selection of variants from the 430-
gene panel, the synonymous variants, variants with variant
frequency <10%, and variants with allele frequency >1%
were removed. The variants were predicted to be pathogenic
by the score of pathogenicity assessment that used using in
silico bioinformatics tools, including Sorting Intolerant
from Tolerant (SIFT) (Genome Institute of Singapore,
http://sift.bii.a-star.edu.sg/) and Polymorphism Phenotyp-
ing v2 (PolyPhen-2) (http://genetics.bwh.harvard.edu/pph2/
index.shtml). For variants with contradictory predictions in
the two pathogenicity assessments, only the 55 genes asso-
ciated with EIEE and EE genes in OMIM were selected for
further analysis. All the variants identified were further con-
firmed by Sanger sequencing, the corresponding gene con-
texts were evaluated according to OMIM with the
individual phenotypes, and they were further assessed by
Mutation Taster (http://www.mutationtaster.org/). The
Exome Aggregation Consortium (ExAC) database (http://
exac.broadinstitute.org/). was consulted for the allele fre-
quencies of these variants. Segregation analysis was carried
out to select de novo or compound heterozygous variants.
The splice site variants were analyzed by another online
software tool, Human Splicing Finder (http://www.umd.be/
Table 1. The 430 genes selected for further filtering
Genes associated with
EIEE and EE in OMIM (55)
AARS, ARHGEF9, ARX, CDKL5, DNM1, DOCK7, EEF1A2, FOXG1, GRIN2B, GABRA1, GNAO1, HCN1, ITPA, KCNA2,
KCNB1, KCNQ2, KCNT1, MAGI2, MECP2, NECAP1, PCDH19, PIGA, PLCB1, PNKP, PNPO, SCN1A, SIK1, SLC12A5,
SLC13A5, SCN2A, SLC25A22, SLC35A2, SCN8A, SPTAN1, ST3GAL3, STXBP1, SZT2, TBC1D24, WWOX, ALG13,
ARHGEF15, CACNA2D2, CBL, CHD2, CLCN4, CSNK1G1, GABRG2, GRIN2A, KCNH5, KPNA7, MAPK10, MBD5, PIGQ,
SRGAP2, SYNGAP1
Candidate genes identified
in exome studies (35)
ADSL, ANK3, CACNA1A, CNTN5, DCX, DNAJC6, FLNA, GABRB1, GRIN1, HDAC4, IQSEC2, MTOR, NEDD4L, PTEN, FASN,
GABBR2, RANGAP1, RYR3, TTN,HADHB, KIAA1456, LPHN2, MTMR1, OR10H2, ZMYND8, ZNF182,
HNRNPU, MEF2C, UBE3A, ASAH1, FOLR1, SYNJ1, CASK, KCND2, KCNV2
Candidate genes from EE or
epilepsy-associated CNVs (53)
ADAM22, ADAM23, AKT3, APBA1, APBA2, CACNA2D1, CHD5, CHL1, CLVS2, CPLX1, CRIPT, CRMP1, DLGAP1, DLGAP2,
DLGAP3, DLX1, DLX2, EFCAB2, EPHA6, EPHB2, EPN1, ERBB4, FZD9, GABRA5, GABRB3, GABRG3, GAD1, GNAI1,
JAKMIP1, KLHL17, MAGEL2, MAPK8, NCAM2, OTX1, RCOR1, PDK1, PPP2R2C, REL, SEMA3A, SEMA3E, SH3GL2,
SHROOM2, SLC1A1, SLC1A3, SMARCA2, SNPH, SP1, STX1A, SV2A, SV2B, SYT2, ZNF532, ZNF536
Genes related to epilepsy or
other neurodevelopmental
diseases (287)
272 genes fromNGS panel by Lemke et al.,11 ASNS, BCKDK, CHRNA7, CPA6, DNAJC5, GATM, GOSR2, GRN, KANSL1,
LIAS, PRRT2, SLC19A3, ST3GAL5, SYN1, UPB1
CNV, copy number variation; EE, epileptic encephalopathy; EIEE, early infantile EE; OMIM, Online Mendelian Inheritance in Man database.
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HSF3/HSF.html). The identified variants were classified as
“pathogenic,” “likely pathogenic,” or “uncertain signifi-
cance,” according to the American College of Medical
Genetics (ACMG) standards and guidelines.12
Results
Thirty-one non-syndromic cryptogenic NIEE patients
were recruited into this study, including 14 patients who had
negative findings in our previous 7-gene panel study.6 We
sequenced the exon regions of these patients by WES. At
least 49.8 million on-target reads after duplicate read
removal were generated per patient. The average on-target
coverage was 589, and the average percentage of coverage
≥8 on-target regions was 96%. The variants called from
WES were filtered in a 430-gene panel that included four
categories of genes: EE genes from OMIM, candidate genes
identified in exome studies, candidate genes from CNV
studies, and genes related to other neurodevelopmental dis-
orders. We have identified variants in 11 NIEE patients
(35%) in our cohort of 31 cases (Table 2). Eight patients
had variants identified in six EE genes (ALG13, CDKL5,
DNM1, KCNQ2, PNPO, and SCN8A) defined by OMIM,
and the other three had variants in two genes related to other
neurodevelopmental disorders, including SLC9A6 which is
associated with Christianson type of syndromic X-linked
mental retardation (MRXSCH), and TUBA8, related to
polymicrogyria with optic nerve hypoplasia. No variant
could be found in the other two categories of genes (candi-
date genes identified in exome and CNV studies) in the
panel. Of these 11 patients with variants found, 9 had vari-
ants that were classified as pathogenic or likely pathogenic
and 2 had variants of uncertain significance (VUS), accord-
ing to the ACMG standards and guidelines (Table 3).
The clinical characteristics of these 11 patients with vari-
ants are listed in Table 2, and most of the clinical pheno-
types of these patients resembled those reported previously
with variants identified in the same genes.
Patient 55 was a PNPO compound heterozygote consist-
ing of a frameshift variant (p.Pro150Argfs*27) and a mis-
sense variant (p.Arg161Gly) which involves a highly
conserved residue Arg161 and was predicted to be an
enzyme active site.13 This patient presented with neonatal
onset EE and negative biochemical markers for pyridox
(am)ine phosphate oxidase (PNPO) deficiency. He had a
transient 2-month complete response to oral vitamin B6 at
30 mg/kg/day, followed by recurrence of intractable sei-
zures at 3 months. Oral pyridoxal phosphate (PLP) at
30 mg/kg/day was then tried for 4 days without any clinical
improvement. After PNPO deficiency was confirmed genet-
ically, PLP was restarted at 40 mg/kg/day, and he became
totally seizure-free. He was able to be weaned off anticon-
vulsants from a total of five to valproate monotherapy. Neu-
rodevelopmental outcome was poor with severe
developmental delay, cortical visual impairment and
autistic features. Our patient illustrated the importance of
adequate therapeutic trial of PLP up to 50 mg/kg/day.14
In addition to the classical phenotype as described by
Smith-Packard15 with early-onset EE and severe psychomo-
tor delay, Patient 75 with a ALG13 variant (p.Asn107Ser)
also had intermittent generalized dystonia and hand stereo-
typies resembling those of other patients in our cohort with
CDKL5 encephalopathy at a slightly later age of onset at
4 months. Despite having a pathogenic variant in a gene
associated with congenital disorder of glycosylation (CDG),
there was no clinical evidence of a multi-systemic disorder
or positive biochemical markers, including transferrin iso-
form electrophoresis, similar to the reported cases.
Details of the variants are summarized in Table 3. Vari-
ants were located in specific domains, which may be impor-
tant for the gene functions and we have included them in the
table. All variants were not found or were found with extre-
mely low allele frequency in controls of the ExAC database.
They were predicted to be pathogenic by all silico prediction
tools (SIFT, Polyphen-2 and Mutation Taster) except for
p.Tyr284His, identified inKCNQ2 and p.Asn107Ser, identi-
fied in ALG13. For Patient 73 with a CDKL5 variant, segre-
gation analysis could not be performed because the DNA of
both parents was not available. However, this is a truncating
variant that was not found in controls of the ExAC database
and is likely to be pathogenic.
Discussion
EE is a group of phenotypically and genotypically hetero-
geneous disorders. In the present study, we recruited a
cohort of EE patients with neonatal and infantile onset. In
addition to the known EE genes in our gene panel, we
included candidate genes from previous exome/CNV stud-
ies and genes associated with other neurodevelopmental dis-
orders to identify more genes associated with these
disorders. A number of criteria, including allele frequency
according to exome sequencing project, pattern of inheri-
tance, and pathogenicity assessed by multiple computa-
tional prediction tools, were applied for variant selection.
Pathogenicity of the variants
Although the pathogenicity assessment of p.Tyr284His
of KCNQ2 was not consistent by different silico prediction
tools, a similar variant p.Tyr284Cys reported previously in
a family affected by benign familial neonatal seizure
(BFNS)16 was demonstrated to decrease axonal surface
expression of KCNQ2 channels by 50%. In addition,
p.Tyr284His is de novo and absent in ExAC controls. There-
fore, it is likely to be pathogenic. Instead of BFNS, our
patients with p.Tyr284His had EE and severe developmen-
tal delay. Some previous studies illustrated that affected
family members carrying the same KCNQ2 variant could
present with different phenotypes ranging from benign
BFNS to severe epileptic encephalopathy.17,18 Such
Epilepsia Open, 2(2):236–243, 2017
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phenotypic variation might be caused by genetic modifiers
and different environmental backgrounds.
The splice site variant c.794-2A>G of SLC9A6was inher-
ited from Patient 7’s asymptomatic mother. As reviewed by
Pesosoido et al.,19 a majority of studies report that the
female carriers of the SLC9A6 variants could be asymp-
tomatic or present with different levels of neurodevelop-
mental or behavioral problems. Most of the pathogenic
SLC9A6 variants identified were truncating.19 Loss of func-
tion of SLC9A6 may possibly decrease endosomal pH and
ion content which may affect the endosomal trafficking
required for the growth and maintenance of dendritic
spines.20 Therefore, the SLC9A6 variant we identified is
likely to be pathogenic.
The DNM1 and TUBA8 variants were classified as VUS.
For the DNM1 variant, DNA of Patient 72’s father was not
available for segregation analysis, so the evidence was not
enough to show p.Pro144Leu of DNM1 is pathogenic
according to ACMG standards, although it is not found in
ExAC controls and is located at the active GTPase domain.
For TUBA8, a 14-bp TUBA8 homozygous deletion was pre-
viously identified in four children of two Pakistani families
and was characterized by generalized polymicrogyria in
association with optic nerve hypoplasia (PMGOH), severe
developmental delay, hypotonia, and seizures. Alpha-8-
tubulin, encoded by TUBA8, was demonstrated to partici-
pate in the microtubule assembly in mammalian cells.21 Our
patient, however, presented with severe intellectual disabil-
ity (ID), developmental regression, hypotonia and seizure
indistinguishable from the other patients in our cohort. Neu-
roimaging was normal, without malformation of cortical
development or optic nerve hypoplasia. More functional
studies should be performed in the future to investigate the
association of TUBA8 defect with NIEE and pathogenicity
of the TUBA8VUS identified in our study.
Insights into diagnostic and treatment strategies
An accurate and early genetic diagnosis is crucial to avoid
unnecessary investigations. This can be exemplified by our
Patient 16 with an SCN8A variant who presented with
intractable NIEE, progressive dementia, and cerebellar
ataxia mimicking a neurodegenerative, possibly mitochon-
drial disorder. Successful identification of this pathogenic
variant could avoid further invasive biopsies for investigat-
ing a possible mitochondrial cytopathy.
More importantly, a successful molecular diagnosis may
allow for a better treatment strategy. For Patient 55, genetic
confirmation of PNPO deficiency prompted a retrial of an
adequate dose of PLP therapy, rendering the patient seizure-
free. Besides, both Patient 16 and 65 with SCN8A variants
had excellent responses to sodium channel blockers such as
carbamazepine and phenytoin. Larsen et al.22 also observed
that a few cases became seizure-free with use of sodium
channel blockers, in contrast to the exacerbating effect to
seizures in Dravet syndrome. This may be due to the
differences in localizations and roles of Nav1.6 and Nav1.1
channels in neuronal excitability.23 In addition to SCN8A
encephalopathy, a recent study showed that carbamazepine
and phenytoin should be considered as first-line treatments
in patients with KCNQ2 encephalopathy because of their
modulating effects on voltage-gated sodium and potassium
channels for reducing neurodevelopmental impairment.24
This further supports the importance of genotype identifica-
tion for a better choice of anticonvulsant in the patients with
different channelopathies. Encouragingly, studies on tar-
geted treatments in genetic NIEE show promising results,
including the use of potassium channel openers such as ezo-
gabine in patients with pathogenicKCNQ2 variants for posi-
tive effects on seizures and/or developmental status.25
Our two patients ultimately diagnosed with PNPO defi-
ciency and CDG illustrated that neurometabolic disorders
can present non-specifically with EE and severe intellectual
disability. Therefore, absence of multi-systemic involve-
ment and/or biochemical metabolic markers does not rule
out inborn errors of metabolism. Diagnosis is essential
because patients may have a potentially treatable disorder,
just like our cases with PNPO deficiency.
Diagnostic rate of variants identified by gene panel
study
The diagnostic rate of pathogenic or likely pathogenic
variants identified in the present study of 31 non-syndromic
NIEE patients by the 430-gene panel analysis was 29%.
This rate is comparable to several recent NIEE studies by
whole exome or gene panel analysis with diagnostic yields
ranging from 18% to 61%.26–30 However, it is not easy to
compare these studies with ours because of the variations in
patient inclusion criteria, number of genes in the targeted
panel, and pipeline applied. Among our 31 patients, 14
patients had negative findings in our previous 7-gene panel
study6 and were subsequently recruited to this study. For
these 14 patients, the present study identified four additional
variants.
Because most of the variants were identified in 55 EE
genes defined by OMIM, the EE gene panel analysis will be
useful as a first-line molecular diagnostic tool to identify the
genetic etiologies of non-syndromic cryptogenic NIEE
patients. It is quicker to analyze gene panels instead of
whole exome data. If the result is negative, the remaining
WES data can be used to detect variants in rarer NIEE genes
or even to discover novel genes.
Our study has several drawbacks. Because of limited to
resources, we used singletons instead of trio-based exome
sequencing, which can narrow down the candidate variants
according to the underlying inheritance patterns. WES can
only identify the genetic defect in coding regions. Non-cod-
ing regulatory defects and structural genomic variants could
not be detected. Another limitation of our study is that array
comparative genomic hybridization (aCGH) was not per-
formed to identify deletion/duplications. If more resources
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are available, aCGH, trio-based studies, WES should be
employed in research to detect more causative genetic
defects in the NIEE patients. Moreover, detection rates in
NGS-based studies will inevitably be improved by the
increased knowledge of the genes that underlie a particular
disorder.
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